Neurotech International Limited
On 12 September 2016 (“Prospectus Date”), Neurotech International Limited (ACN 610 205 402) (“Neurotech” or “the Company”) lodged a prospectus (“Prospectus”) with the Australian Securities and Investments Commission (“ASIC”) for the offer of 35,000,000 fully paid ordinary shares in the Company (“Shares”) at an issue price of 20 cents per Share to raise $7,000,000, and the offer of up to 2,529,076 options to acquire Shares to the Lead Manager (as those terms are defined in the Prospectus).
THE OFFER HAS NOW CLOSED, AND THE COMPANY IS NO LONGER ACCEPTING APPLICATIONS FOR SHARES.
An electronic copy of the Prospectus can be obtained in PDF format by clicking below after confirming agreement to the following.
This is an important document that should be read in its entirety. If you do not understand it, you should consult your professional adviser without delay. The paper form of the electronic Prospectus is accessible through this website has been lodged with ASIC.
Applications for securities referred to in the Prospectus must be made in accordance with the terms and conditions set out in the Prospectus. Applications for securities must be made on an application form that accompanies a complete hard copy of the Prospectus. There is no facility for online applications.
The Company will not issue any Shares on the basis of this Prospectus later than 13 months after the Prospectus Date.
The Prospectus does not constitute an offer in any place in which, or to any person to whom, it will not be lawful to make such an offer. No action has been taken to lodge, register or file the Prospectus in any jurisdiction outside Australia. The distribution of this Prospectus outside Australia may be restricted by law and persons who come into possession of this Prospectus outside Australia should seek advice on and observe any such restrictions. The investment described in this Prospectus has not been recommended by any regulatory authority of any jurisdiction including ASIC.
The information on this website is provided for information purposes only and is subject to change without notice. Nothing contained on this website or in the Prospectus constitutes investment, legal, accounting, business, tax or other advice. The information on this website and in the Prospectus does not take into account your investment objectives, financial situation or particular needs. The information on this website does not form part of the Prospectus.
By accessing the Prospectus, you are taken to have confirmed that you have read and understood the notice and agree to these terms and conditions.
Neurotech International Limited, or Neurotech, is a medical device and solutions company incorporated in Australia, operating through its wholly-owned, Malta-based subsidiary, AAT Research Limited.
Our primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions which are accessible and affordable. Through our first flagship medical device, Mente Autism, and the associated software platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism. The development of the Mente Autism headband, now in its third iteration, represents years of research, testing and pilot studies, to effectively bring a highly specialised treatment for the management of autism, from the hospitals and clinics, into the comfort and familiarity of a patient’s home.
In doing so, Neurotech and the Mente technology sit at the confluence of several market forces, including a heightened focus on understanding the brain, the increasing diagnosis of neurological conditions and the increasing adoption of home-based precision healthcare.